Table 1.
Variable | FoG | nFoG | P value |
---|---|---|---|
Number | 20 | 18 | – |
Age (y) | 57.60 (11.48) 26–73 |
67.44 (6.02) 56–78 |
0.004 |
Gender (F/M) | 6/14 | 5/13 | – |
Disease duration (y) | 12.65 (5.63) | 6.47 (4.17) | <0.001 |
5–26 | 2–17 | ||
UPDRS Part III | 33.50 (11.05) | 28.50 (10.48) | 0.192 |
17–54 | 9–47 | ||
LEDD | 753.80 (488.20) | 437.50 (291.10) | 0.012 |
150–2400 | 50–1200 | ||
NFOGQ | 18.95 (6.30) | 0 | – |
7–29 | |||
APA duration (ms) | 253.00 (84.61) | 210.00 (58.93) | 0.133 |
126.16–421.87 | 143.75–356.91 | ||
APA amplitude (normalized) | 0.35(0.08) | 0.33 (0.08) | 0.545 |
0.22–0.49 | 0.16–0.46 |
In bold: significant results (p < 0.05) of Mann-Whitney two-tailed. Abbreviations: UPDRS Part III (Unified Parkinson’s Disease Rating Sale Part III); H&Y (Hoehn & Yahr scale); LEDD (levodopa equivalent daily dose); NFOGQ (New Freezing of Gait Questionnaire); APA (anticipatory postural adjustment).